Mutant CALR BiTEs and antibody-drug conjugates
Current understanding
To be populated as evidence accumulates.
Evidence log
Open questions
Related
Contributing findings
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.
18-aug-2026
novelty 2
per-area 3
introduces